Evidence map›Paper›PMID 35023287›Full record

ArticleHIV medicine2022

Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa.

Jaysingh Brijkumar, Johnathan A Edwards, Brent A Johnson, Claudia Ordonez, Henry Sunpath, Mitch Lee, Mathew R Dudgeon, Lydia Rautman, Selvan Pillay, Pravi Moodley and 6 more

Open access · greenAbstract read
In one paragraph

Article in HIV medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Jaysingh BrijkumarUniversity of KwaZulu Natal, Nelson R Mandela School of Medicine, Durban, South Africa.ORCID 0000-0002-3511-2112
Johnathan A EdwardsEmory University Rollins School of Public Health, Atlanta, Georgia, USA.
Brent A JohnsonUniversity of Rochester, Rochester, New York, USA.
Claudia OrdonezEmory University Rollins School of Public Health, Atlanta, Georgia, USA.
Henry SunpathUniversity of KwaZulu Natal, Nelson R Mandela School of Medicine, Durban, South Africa.
Mitch LeeEmory University Rollins School of Public Health, Atlanta, Georgia, USA.
Mathew R DudgeonEmory University Rollins School of Public Health, Atlanta, Georgia, USA.
Lydia RautmanEmory University Rollins School of Public Health, Atlanta, Georgia, USA.
Selvan PillayUniversity of KwaZulu Natal, Nelson R Mandela School of Medicine, Durban, South Africa.
Pravi MoodleyUniversity of KwaZulu-Natal, School of Laboratory Medicine and Medical Sciences, National Health Laboratory Service, Durban, South Africa.
Y V SunEmory University Rollins School of Public Health, Atlanta, Georgia, USA.
José Castillo-MancillaUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0003-1242-1745
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Daniel R KuritzkesBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mohamed Y S MoosaUniversity of KwaZulu Natal, Nelson R Mandela School of Medicine, Durban, South Africa.
Vincent Charles MarconiEmory University Rollins School of Public Health, Atlanta, Georgia, USA.
Emory University · USUniversity of KwaZulu-Natal · ZABrigham and Women's Hospital · USNational Health Laboratory Service · ZAUniversity of Colorado Anschutz Medical Campus · USUniversity of Rochester · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African AncestryR01DK125187 · NIDDK · EMORY UNIVERSITY · PI MARCONI, VINCENT CHARLES, SUN, YAN · 2020 to 2024
$4.1M
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous systemR01MH128158 · NIMH · EMORY UNIVERSITY · PI Christina Gavegnano, Vincent Charles Marconi · 2022 to 2026
$3.2M
Antiretroviral drug resistance in KwaZulu NatalR01AI098558 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KURITZKES, DANIEL R., MARCONI, VINCENT CHARLES · 2013 to 2017
$2.3M
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI098558NIDDK NIH HHS R01 DK125187NIMH NIH HHS R01 MH128158
6 · The paper itself

Abstract

objectivesViral suppression (VS) is the hallmark of successful antiretroviral therapy (ART) programmes. We sought to compare clinic retention, virological outcomes, drug resistance and mortality between peri-urban and rural settings in South Africa after first-line ART.

methodsBeginning in July 2014, 1000 (500 peri-urban and 500 rural) ART-naïve patients with HIV were enrolled and managed according to local standard of care. Clinic retention, virological suppression, virological failure (VF), genotypic drug resistance and mortality were assessed. The definition of VS was a viral load ≤1000 copies/ml. Time to event analyses were stratified by site, median age and gender. Kaplan-Meier curves were calculated and graphed with log-rank modelling to compare curves.

resultsBased on 2741 patient-years of follow-up, retention and mortality did not differ between sites. Among all 1000 participants, 47%, 84% and 91% had achieved VS by 6, 12 and 24 months, respectively, which was observed earlier in the peri-urban site. At both sites, men aged < 32 years had the highest proportion of VF (15.5%), while women aged > 32 years had the lowest, at 7.1% (p = 0.018). Among 55 genotypes, 42 (76.4%) had at one or more resistance mutations, which did not differ by site. K103N (59%) and M184V (52%) were the most common mutations, followed by V106M and K65R (31% each). Overall, death was infrequent (< 4%).

conclusionsNo significant differences in treatment outcomes between peri-urban and rural clinics were observed. In both settings, young men were especially susceptible to clinic attrition and VF. More effective adherence support for this important demographic group is needed to achieve UNAIDS targets.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsAnti-Retroviral AgentsDrug Resistance, ViralFemaleHumansMaleSouth AfricaViral LoadAnti-HIV AgentsAnti-Retroviral Agentsclinic retentiondispositiondrug resistancevirological failurevirological suppression

Identifiers

PMID35023287
PMCPMC9353676
OpenAlexW4205667596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.